PL2179744T3 - Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie - Google Patents

Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie

Info

Publication number: PL2179744T3
Authority: PL; Poland
Prior art keywords: latrogenic; risks associated; influenza vaccines; decreasing potential; pathogens
Prior art date: 2004-09-09

Application number

PL09075377T

Other languages

English (en)

Inventor

Jens Peter Gregersen

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-09

Filing date

2005-09-09

Publication date

2011-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35520177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2179744(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-09 Application filed by Novartis Ag filed Critical Novartis Ag

2011-09-30 Publication of PL2179744T3 publication Critical patent/PL2179744T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Pathology (AREA)

PL09075377T 2004-09-09 2005-09-09 Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie PL2179744T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04255471		2004-09-09
EP05795012A EP1789084B1 (en)	2004-09-09	2005-09-09	Decreasing potential iatrogenic risks associated with influenza vaccines
EP20090075377 EP2179744B1 (en)	2004-09-09	2005-09-09	Decreasing potential latrogenic risks associated with influenza vaccines

Publications (1)

Publication Number	Publication Date
PL2179744T3 true PL2179744T3 (pl)	2011-09-30

Family

ID=35520177

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL05795012T PL1789084T3 (pl)	2004-09-09	2005-09-09	Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
PL09075377T PL2179744T3 (pl)	2004-09-09	2005-09-09	Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
PL10075310T PL2236155T3 (pl)	2004-09-09	2005-09-09	Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie
PL12193096T PL2578229T3 (pl)	2004-09-09	2005-09-09	Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL05795012T PL1789084T3 (pl)	2004-09-09	2005-09-09	Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL10075310T PL2236155T3 (pl)	2004-09-09	2005-09-09	Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie
PL12193096T PL2578229T3 (pl)	2004-09-09	2005-09-09	Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce

Country Status (15)

Country	Link
US (6)	US8119337B2 (pl)
EP (5)	EP2236155B1 (pl)
JP (7)	JP2008512443A (pl)
AT (2)	ATE488248T1 (pl)
CA (2)	CA2890962A1 (pl)
CY (3)	CY1111180T1 (pl)
DE (3)	DE602005025170D1 (pl)
DK (4)	DK2236155T3 (pl)
ES (4)	ES2386272T3 (pl)
HR (4)	HRP20100673T1 (pl)
PL (4)	PL1789084T3 (pl)
PT (4)	PT1789084E (pl)
RS (3)	RS52400B (pl)
SI (4)	SI2236155T1 (pl)
WO (1)	WO2006027698A1 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1789084E (pt) *	2004-09-09	2011-02-22	Novartis Vaccines & Diagnostic	Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
ES2310062B1 (es)	2005-07-15	2009-11-13	Bionostra, S.L.	Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
WO2007052163A2 (en) *	2005-11-01	2007-05-10	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
PL1951299T3 (pl)	2005-11-04	2012-07-31	Novartis Ag	Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
US20110180430A1 (en)	2005-11-04	2011-07-28	Novartis Vaccines And Diagnostics Srl	Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628206A1 (en)	2005-11-04	2007-05-10	Novartis Vaccines And Diagnostics S.R.L.	Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2368572B1 (en)	2005-11-04	2020-03-04	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310246B2 (en)	2005-11-04	2010-12-23	Seqirus UK Limited	Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
DK2478916T3 (da)	2006-01-27	2020-06-15	Seqirus Uk Ltd	Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
WO2007110776A1 (en)	2006-03-24	2007-10-04	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Storage of influenza vaccines without refrigeration
JP2009532352A (ja)	2006-03-31	2009-09-10	ダブリュエーアールエフ−ウィスコンシンアラムナイリサーチファウンデーション	ワクチンのための高力価組み換えインフルエンザ・ウィルス
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
AU2007297178B2 (en)	2006-09-11	2014-07-24	Novartis Ag	Making influenza virus vaccines without using eggs
WO2008059018A2 (en) *	2006-11-15	2008-05-22	Intervet International B.V.	Vaccine for vaccinating felines and canines against influenza virus
EA200900784A1 (ru)	2006-12-06	2009-12-30	Новартис Аг	Вакцины, включающие антиген из четырех штаммов вируса гриппа
US9474798B2 (en)	2007-06-18	2016-10-25	Wisconsin Alumni Research Foundation	Influenza M2 protein mutant viruses as live influenza attenuated vaccines
US20100183671A1 (en)	2007-06-27	2010-07-22	Novartis Vaccines & Diagnostics GmbH & Co., KG	Low-additive influenza vaccines
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
EP2889042A3 (en)	2008-03-18	2015-10-14	Novartis AG	Improvements in preparation of influenza virus vaccine antigens
WO2010052214A2 (en)	2008-11-05	2010-05-14	Glaxosmithkline Biologicals S.A.	Novel method
EP2396030B1 (en)	2009-02-10	2015-08-12	Novartis AG	Influenza vaccine regimens for pandemic-associated strains
US9278126B2 (en)	2009-02-10	2016-03-08	Seqirus UK Limited	Influenza vaccines with reduced amounts of squalene
EP2396031A1 (en)	2009-02-10	2011-12-21	Novartis AG	Influenza vaccines with increased amounts of h3 antigen
FR2949344A1 (fr)	2009-04-27	2011-03-04	Novartis Ag	Vaccins de protection contre la grippe
CA2773637A1 (en)	2009-09-10	2011-03-17	Novartis Ag	Combination vaccines against respiratory tract diseases
WO2011056591A1 (en)	2009-10-26	2011-05-12	Warf - Wisconsin Alumni Research Foundation	High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en)	2010-03-23	2018-11-20	Wisconsin Alumni Research Foundation (Warf)	Vaccines comprising mutant attenuated influenza viruses
CN102858961A (zh) *	2010-05-03	2013-01-02	葛兰素史密丝克莱恩生物有限公司	新方法
JP5876036B2 (ja)	2010-05-21	2016-03-02	ノバルティスアーゲー	インフルエンザウイルス再集合方法
PT2575873E (pt)	2010-06-01	2016-03-04	Novartis Ag	Concentração de antigénios de vacinas com liofilização
CN103096921A (zh)	2010-06-01	2013-05-08	诺华有限公司	不用冻干疫苗抗原浓缩
GB201011502D0 (en)	2010-07-08	2010-08-25	Glaxosmithkline Biolog Sa	Novel process
EP2605792B1 (en)	2010-08-20	2014-12-10	Novartis AG	Soluble needle arrays for delivery of influenza vaccines
CA2812135A1 (en)	2010-09-07	2012-03-15	Novartis Ag	Generic assays for detection of mammalian reovirus
WO2012114312A2 (en)	2011-02-25	2012-08-30	Novartis Ag	Exogenous internal positive control
WO2013057715A1 (en)	2011-10-20	2013-04-25	Novartis Ag	Adjuvanted influenza b virus vaccines for pediatric priming
EP2791680B1 (en) *	2011-12-12	2015-12-09	Novartis AG	Assay for influenza virus hemagglutinins
GB201218195D0 (en)	2012-10-10	2012-11-21	Istituto Zooprofilattico Sperimentale Delle Venezie	Composition
JP2016524915A (ja)	2013-07-15	2016-08-22	ウィスコンシンアルムニリサーチファンデイション	Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
EP3105311A1 (en)	2014-02-10	2016-12-21	Univercells NV	System, apparatus and method for biomolecules production
RU2628800C2 (ru) *	2014-03-12	2017-08-22	Общество С Ограниченной Ответственностью "Фарминтерпрайсез"	Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
WO2015196150A2 (en)	2014-06-20	2015-12-23	Wisconsin Alumni Research Foundation (Warf)	Mutations that confer genetic stability to additional genes in influenza viruses
AR102548A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
MA40920A (fr)	2014-11-07	2017-09-12	Takeda Vaccines Inc	Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
US10633422B2 (en)	2015-06-01	2020-04-28	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
AU2016281904B2 (en)	2015-06-26	2022-08-11	Seqirus UK Limited	Antigenically matched influenza vaccines
US9890363B2 (en)	2015-07-06	2018-02-13	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication for vaccine development
AU2016290603B2 (en)	2015-07-07	2022-06-02	Seqirus UK Limited	Influenza potency assays
CA3014435C (en)	2016-02-19	2023-04-18	Wisconsin Alumni Research Foundation (Warf)	Improved influenza b virus replication for vaccine development
EP3700562A1 (en)	2017-10-25	2020-09-02	Wisconsin Alumni Research Foundation (WARF)	Recombinant influenza viruses with stabilized ha for replication in eggs
WO2019086463A1 (en)	2017-10-30	2019-05-09	Baxalta GmbH	Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019090228A2 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
JP2021533157A (ja)	2018-08-07	2021-12-02	ウィスコンシンアルムニリサーチファンデイション	組換えの生物学的に封じ込められたフィロウイルスワクチン
WO2020041311A1 (en)	2018-08-20	2020-02-27	Wisconsin Alumni Research Foundation	Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
AU2019362833A1 (en) *	2018-10-15	2021-04-29	Regenxbio Inc.	Method for measuring the infectivity of replication defective viral vectors and viruses
JP2022527235A (ja)	2019-01-23	2022-06-01	義裕河岡	インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
WO2020163804A1 (en)	2019-02-08	2020-08-13	Wisconsin Alumni Research Foundation (Warf)	Humanized cell line
US11390649B2 (en)	2019-05-01	2022-07-19	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication for vaccine development
US20220211836A1 (en)	2019-05-08	2022-07-07	Takeda Vaccines, Inc.	Inactivated virus compositions and zika vaccine formulations
EP4022046A2 (en)	2019-08-27	2022-07-06	Wisconsin Alumni Research Foundation (WARF)	Recombinant influenza viruses with stabilized ha for replication in eggs
US20230000971A1 (en)	2019-11-18	2023-01-05	Seqirus Pty Ltd.	Method for producing reassortant influenza viruses
JP2023511444A (ja) *	2020-01-24	2023-03-17	ウィスコンシンアルムニリサーチファンデイション	安定化されたｎａを有する組換えインフルエンザウイルス
US12290562B2 (en)	2020-03-25	2025-05-06	Wisconsin Alumni Research Foundation (Warf)	Recombinant multivalent influenza viruses
WO2022187230A2 (en) *	2021-03-01	2022-09-09	Iowa State University Research Foundation, Inc.	Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof
CN114107392A (zh) *	2021-11-22	2022-03-01	昆明理工大学	一种cvb5病毒类病毒样颗粒的制备方法
EP4476329A1 (en)	2022-02-09	2024-12-18	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4193991A (en)	1978-12-20	1980-03-18	Cornell Research Foundation, Inc.	Canine parvovirus vaccine
EP0261955A3 (en) *	1986-09-26	1989-06-07	E.I. Du Pont De Nemours And Company	Process for immobilization of dna
US6284492B1 (en) *	1988-02-26	2001-09-04	Large Scale Biology Corporation	Recombinant animal viral nucleic acids
CA2054228A1 (en)	1990-10-30	1992-05-01	Masaharu Oki	Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
JPH0813753B2 (ja) *	1992-05-22	1996-02-14	株式会社微生物化学研究所	牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン
IL103939A (en) *	1992-12-01	1996-09-12	Abic Ltd	An anti-DBI vaccine in birds containing attenuated live DBI virus
WO1994019013A1 (en)	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE4311580C1 (de) *	1993-04-12	1994-08-18	Werner Prof Dr Med Reutter	Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5824536A (en) *	1994-08-23	1998-10-20	St. Jude Children's Research Hospital	Influenza virus replicated in mammalian cell culture and vaccine production
DK1213030T3 (da)	1994-11-10	2009-07-20	Baxter Healthcare Sa	Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur
US6146873A (en) *	1994-11-10	2000-11-14	Baxter Aktiengesellschaft	Production of orthomyxoviruses in monkey kidney cells using protein-free media
GB9500788D0 (en)	1995-01-16	1995-03-08	Medeva Holdings Bv	Vaccine compositions
DE19612967A1 (de) *	1996-04-01	1997-10-02	Behringwerke Ag	Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de)	1996-04-01	2009-12-10	Novartis Vaccines And Diagnostics Gmbh & Co. Kg	MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en)	1997-04-09	2004-01-11	Duphar Int Res	Influenza vaccine
JPH1175833A (ja) *	1997-06-23	1999-03-23	Chemo Sero Therapeut Res Inst	トリレオウイルスの調製法
GB9725084D0 (en)	1997-11-28	1998-01-28	Medeva Europ Ltd	Vaccine compositions
CN1309708A (zh)	1997-12-11	2001-08-22	萨斯喀彻温大学	来源于猪的断奶后多系统消耗综合症病毒
GB9804632D0 (en) *	1998-03-05	1998-04-29	Cantab Pharma Res	Virus preparations and methods
AT408615B (de)	1998-09-15	2002-01-25	Immuno Ag	Neue influenzavirus-impfstoffzusammensetzung
US6855544B1 (en) *	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
GB9923176D0 (en)	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
EP1103610A1 (en) *	1999-11-26	2001-05-30	Introgene B.V.	Production of vaccines from immortalised mammalian cell lines
US7192759B1 (en) *	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
DOP2000000109A (es) *	1999-12-23	2002-08-30	Gerald Kleymann	Derivados de tiazolilamida
TWI228420B (en)	2001-05-30	2005-03-01	Smithkline Beecham Pharma Gmbh	Novel vaccine composition
DE10144903A1 (de) *	2001-09-12	2003-03-27	Chiron Behring Gmbh & Co	Vermehrung von Viren in Zellkultur
DE10144906B4 (de)	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr)	2002-03-08	2005-01-14	Vivalis	Lignees de cellules aviaires utiles pour la production de substances d'interet
KR101229202B1 (ko) *	2002-04-26	2013-02-01	메디뮨 엘엘씨	인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
DE10221836A1 (de) *	2002-05-16	2003-12-04	Lohmann Animal Health Gmbh	Attenuierung von Metapneumovirus
JP2005532057A (ja) *	2002-07-09	2005-10-27	バクスター・インターナショナル・インコーポレイテッド	細胞を培養するための動物性タンパク質非含有培地
JP3957188B2 (ja) *	2002-10-25	2007-08-15	▲あき▼夫友田	抗ウィルス剤
EP1596884A2 (en)	2003-01-30	2005-11-23	Medimmune, Inc.	Uses of integrin alphavbeta3 antagonists
EP2494987A1 (en) *	2003-04-25	2012-09-05	MedImmune Vaccines, Inc.	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1528101A1 (en)	2003-11-03	2005-05-04	ProBioGen AG	Immortalized avian cell lines for virus production
PT1789084E (pt) *	2004-09-09	2011-02-22	Novartis Vaccines & Diagnostic	Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
NZ582019A (en)	2007-06-14	2012-07-27	Univ Oklahoma State	Vaccines containing canine parvovirus genetic variants

2005
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 HR HR20100673T patent/HRP20100673T1/hr unknown
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en active Active
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en active Active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en active Active
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
2012
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending

Also Published As

Publication number	Publication date
RS51721B (en)	2011-10-31
JP2017057209A (ja)	2017-03-23
HRP20100673T1 (hr)	2011-02-28
US20120034600A1 (en)	2012-02-09
HK1144374A1 (en)	2011-02-18
EP2236155B1 (en)	2012-05-16
SI1789084T1 (sl)	2011-03-31
US10155932B2 (en)	2018-12-18
HRP20130962T1 (hr)	2013-12-06
SI2179744T1 (sl)	2011-04-29
PT2236155E (pt)	2012-07-19
JP2015205929A (ja)	2015-11-19
SI2236155T1 (sl)	2012-09-28
HK1105364A1 (en)	2008-02-15
JP2011207911A (ja)	2011-10-20
EP1789084A1 (en)	2007-05-30
US20090081252A1 (en)	2009-03-26
CA2579859C (en)	2015-12-08
EP2179744B1 (en)	2010-12-01
RS52400B (en)	2013-02-28
WO2006027698A1 (en)	2006-03-16
US20190078060A1 (en)	2019-03-14
CY1113225T1 (el)	2016-04-13
DK2578229T3 (da)	2013-10-07
JP2008512443A (ja)	2008-04-24
EP2471551A3 (en)	2012-11-14
US9220768B2 (en)	2015-12-29
PL2578229T3 (pl)	2014-01-31
EP2578229B1 (en)	2013-07-10
US9358280B2 (en)	2016-06-07
US20160251631A1 (en)	2016-09-01
HRP20120640T1 (hr)	2012-08-31
EP2236155A1 (en)	2010-10-06
RS51665B (en)	2011-10-31
CY1111180T1 (el)	2015-06-11
DE602005024827D1 (de)	2010-12-30
PT2179744E (pt)	2011-03-09
ES2432655T3 (es)	2013-12-04
HRP20110007T1 (hr)	2011-04-30
DK2179744T3 (da)	2011-01-31
DE602005025170D1 (de)	2011-01-13
PT2578229E (pt)	2013-09-27
EP2578229A1 (en)	2013-04-10
EP1789084B1 (en)	2010-11-17
CY1111208T1 (el)	2015-06-11
US8460914B2 (en)	2013-06-11
ES2386272T3 (es)	2012-08-16
DK1789084T3 (da)	2011-01-10
PL2236155T3 (pl)	2012-10-31
CA2579859A1 (en)	2006-03-16
DE12193096T1 (de)	2013-07-25
PT1789084E (pt)	2011-02-22
EP2179744A1 (en)	2010-04-28
ES2357752T3 (es)	2011-04-29
ATE489965T1 (de)	2010-12-15
JP2012025784A (ja)	2012-02-09
EP2471551B1 (en)	2017-02-01
CA2890962A1 (en)	2006-03-16
DK2236155T3 (da)	2012-08-13
EP2471551A2 (en)	2012-07-04
US20130129782A1 (en)	2013-05-23
JP2019210292A (ja)	2019-12-12
US10954493B2 (en)	2021-03-23
SI2578229T1 (sl)	2013-10-30
JP2013100358A (ja)	2013-05-23
US8119337B2 (en)	2012-02-21
ATE488248T1 (de)	2010-12-15
ES2357747T3 (es)	2011-04-29
PL1789084T3 (pl)	2011-05-31
US20130122487A1 (en)	2013-05-16

Publication	Publication Date	Title
SI2179744T1 (sl)	2011-04-29	Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
BR112013031992A2 (pt)	2016-12-20	sistemas e métodos para criar mapas de prescrição e parcelas
MX2021006342A (es)	2022-05-26	Mutantes de virus de influenza y usos para los mismos.
IL190775A (en)	2016-04-21	Influenza virus-like particles, vaccines containing them and their uses
PT1951300E (pt)	2011-09-05	Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
CL2011000914A1 (es)	2012-01-20	Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
WO2011106607A3 (en)	2011-10-27	Subunit vaccines for herpes viruses and methods of use
MX2009006469A (es)	2009-06-26	Metodo de duplicacion del virus de la influenza en cultivo.
CL2011000913A1 (es)	2012-01-20	Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.
IL213189A (en)	2015-10-29	Vaccine comprising avian influenza antigen, method of vaccinating an animal therewith, dna encoding the antigen and uses thereof
WO2008127296A3 (en)	2009-02-26	Methods and compositions for treating tularemia
PT2368572T (pt)	2020-06-16	Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
WO2006063053A3 (en)	2006-12-07	Methods of producing influenza vaccine compositions
GB2450599A (en)	2008-12-31	Automated culture of stem cells
WO2012125525A3 (en)	2013-02-28	Equine rhinitis vaccine
MX2012002702A (es)	2012-03-21	Vacuna de herpesvirus bovino.
WO2005010173A3 (fr)	2005-05-26	Procede de culture de keratinocytes et ses applications
UA38029U (ru)	2008-12-25	Способ инактивации бактерий при производстве вакцин
WO2014087314A3 (en)	2014-07-31	A light